Clinical Trials

27 enrolled

Phase 2 Not yet recruiting

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07081607 2025-07-23

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

30 enrolled

Lymphoma, T-Cell, Peripheral

NCT01290302 2025-06-12

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

38 enrolled 14 charts

Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT07012447 2025-06-10

Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations

32 enrolled

Phase 1 Active not recruiting

Leukemia, Biphenotypic, Acute, Pyloric Stenosis, Hypertrophic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01333046 2025-06-05

TACTAL

36 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT04752163 2025-05-23

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Phase 1/2 Terminated

17 enrolled 15 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06686108 2025-05-07

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

59 enrolled

Leukemia, Recurrence, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04578600 2025-04-24

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

8 enrolled

Leukemia, Hairy Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04988555 2025-04-02

A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation

Phase 1/2 Recruiting

362 enrolled

Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

GastrointestinalLymphoidOther hematologic neoplasmSarcoma

272 enrolled

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT02828358 2025-02-27

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

Phase 2 Completed

78 enrolled 15 charts

Phase 2 Not yet recruiting

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT06778902 2025-01-16

Dragon

80 enrolled

LymphoidSarcoma

Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT05958719 2024-12-30

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

37 enrolled

Lymphoma, T-Cell, Peripheral

NCT05376111 2024-12-27

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

28 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05476770 2024-12-06

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Phase 1 Recruiting

54 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Hodgkin Disease, Leukemia, Biphenotypic, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03450343 2024-10-28

Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma

9 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

LymphoidOther hematologic neoplasmPlasma cell

189 enrolled

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

NCT03703375 2024-07-08

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Phase 3 Active not recruiting

93 enrolled 19 charts

Lymphoma, Lymphoma, T-Cell

NCT04722601 2024-05-16

A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma

Phase 1/2 Terminated

2 enrolled 7 charts

Lymphoma, Follicular

NCT05107856 2024-01-31

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

21 enrolled

Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT02543879 2023-11-21

Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies

94 enrolled

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03542266 2023-08-22

CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

Phase 2 Completed

21 enrolled 11 charts

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT03465540 2023-04-12

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

LymphoidMyeloidOther hematologic neoplasmPlasma cell

24 enrolled 21 charts

Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05797948 2023-04-04

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase NA Unknown

20 enrolled

Recurrence, Lymphoma, B-Cell

NCT05772728 2023-03-16

Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL)

Phase NA Unknown

23 enrolled

Lymphoma, T-Cell

NCT05559008 2022-11-09

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Phase 1/2 Unknown

116 enrolled

Lymphoma, T-Cell, Peripheral

NCT01241786 2022-07-20

VZCLLPI0146

Phase 2 Terminated

5 enrolled 10 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03161223 2022-03-31

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Phase 1/2 Recruiting

148 enrolled

Lymphoma, T-Cell

NCT05008666 2021-08-17

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

Phase 2 Unknown

37 enrolled

LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

NCT04899414 2021-05-24

Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma

Phase 2 Unknown

50 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT04052659 2021-03-09

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Phase 2 Unknown

30 enrolled

Lymphoma, T-Cell, Peripheral

NCT02951156 2020-12-17

Javelin DLBCL

Phase 3 Terminated

29 enrolled 24 charts

Lymphoma, Large B-Cell, Diffuse

NCT02458235 2020-10-12

Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation

Phase 2 Completed

17 enrolled 12 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT02343536 2020-08-28

A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma

59 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies